NEW YORK (GenomeWeb) – Qiagen has entered into a collaboration and comarketing agreement with Centogene, a German firm focusing on genetic diagnosis of rare disease, in an attempt to integrate sample-to-insight research with clinical testing for rare conditions.

The centerpiece of the agreement is the integration of Centogene's CentoMD database of 4.5 million clinically annotated phenotype and genotype variants of rare diseases into the Qiagen Clinical Insight bioinformatics platform and companion knowledge base.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.